The current COVID-19 pandemic, illustrates how vulnerable the world is to viral infections. There is a strategic need for new approaches to treat patients exposed to viruses without creating drug resistance and to protect high risk patients. A new class of antiviral drugs is needed to change the paradigm from having “one drug against one virus” to “one drug against multiple viruses”
To develop and commercialize our small molecule platform of broad spectrum anti-viral drugs to overcome the clinical challenge of current and future viral infections via a single mechanism, rather than the present piecemeal approach to individual viruses.
Copyright © 2022 ViroCarb Inc. - All Rights Reserved.